Haleon plc

LSE HLN.L

Haleon plc Revenue for the year ending December 31, 2023: USD 14.38 B

Haleon plc Revenue is USD 14.38 B for the year ending December 31, 2023, a 9.58% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Haleon plc Revenue for the year ending December 31, 2022 was USD 13.12 B, a 1.60% change year over year.
  • Haleon plc Revenue for the year ending December 31, 2021 was USD 12.92 B, a -4.38% change year over year.
  • Haleon plc Revenue for the year ending December 31, 2020 was USD 13.51 B, a 20.22% change year over year.
  • Haleon plc Revenue for the year ending December 31, 2019 was USD 11.24 B.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
LSE: HLN.L

Haleon plc

CEO Mr. Brian James McNamara
IPO Date July 18, 2022
Location United Kingdom
Headquarters Building 5
Employees 25,408
Sector Health Care
Industries
Description

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Similar companies

RKT.L

Reckitt Benckiser Group plc

USD 59.37

-0.51%

MNG.L

M&G plc

USD 2.36

1.48%

LGEN.L

Legal & General Group Plc

USD 2.73

1.22%

GSK.L

GSK plc

USD 15.79

-2.73%

StockViz Staff

January 15, 2025

Any question? Send us an email